WO2004106941A3 - Secreted polypeptide species associated with cardiovascular disorders - Google Patents

Secreted polypeptide species associated with cardiovascular disorders Download PDF

Info

Publication number
WO2004106941A3
WO2004106941A3 PCT/EP2004/005786 EP2004005786W WO2004106941A3 WO 2004106941 A3 WO2004106941 A3 WO 2004106941A3 EP 2004005786 W EP2004005786 W EP 2004005786W WO 2004106941 A3 WO2004106941 A3 WO 2004106941A3
Authority
WO
WIPO (PCT)
Prior art keywords
cardiovascular disorders
secreted polypeptide
species associated
polypeptide species
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2004/005786
Other languages
French (fr)
Other versions
WO2004106941A2 (en
Inventor
Lydie Bougueleret
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH Austria
Genova Ltd
Original Assignee
Novartis Pharma GmbH Austria
Genova Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma GmbH Austria, Genova Ltd filed Critical Novartis Pharma GmbH Austria
Priority to JP2006529944A priority Critical patent/JP2007513063A/en
Priority to EP04735211A priority patent/EP1634086A2/en
Publication of WO2004106941A2 publication Critical patent/WO2004106941A2/en
Publication of WO2004106941A3 publication Critical patent/WO2004106941A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention discloses human secreted polypeptides that circulate at an increased level in the plasma of patients with cardiovascular disorders. The invention also provides methods of using compositions including the polypeptides, polynucleotides encoding them, and antibodies specific for these polypeptides, for diagnosis, prognosis, and for drug development.
PCT/EP2004/005786 2003-05-30 2004-05-28 Secreted polypeptide species associated with cardiovascular disorders Ceased WO2004106941A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2006529944A JP2007513063A (en) 2003-05-30 2004-05-28 Secreted polypeptide species associated with cardiovascular disorders
EP04735211A EP1634086A2 (en) 2003-05-30 2004-05-28 Secreted polypeptide species associated with cardiovascular disorders

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US47508303P 2003-05-30 2003-05-30
US47512103P 2003-05-30 2003-05-30
US47508203P 2003-05-30 2003-05-30
US60/475,121 2003-05-30
US60/475,082 2003-05-30
US60/475,083 2003-05-30
US48410203P 2003-06-30 2003-06-30
US60/484,102 2003-06-30

Publications (2)

Publication Number Publication Date
WO2004106941A2 WO2004106941A2 (en) 2004-12-09
WO2004106941A3 true WO2004106941A3 (en) 2005-05-26

Family

ID=33494283

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/005786 Ceased WO2004106941A2 (en) 2003-05-30 2004-05-28 Secreted polypeptide species associated with cardiovascular disorders

Country Status (3)

Country Link
EP (1) EP1634086A2 (en)
JP (1) JP2007513063A (en)
WO (1) WO2004106941A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835545B2 (en) 2000-05-08 2004-12-28 President And Fellows Of Harvard College Methods, products and treatments for diabetes
US7439330B2 (en) 2000-05-08 2008-10-21 President And Fellows Of Harvard College Anti-glycated CD59 antibodies and uses thereof
FI118265B (en) * 2004-01-15 2007-09-14 Jurilab Ltd Oy Procedure for detecting the risk of acute myocardial infarction or coronary artery disease
US7833725B2 (en) 2005-01-06 2010-11-16 President And Fellows Of Harvard College Mass spectrometric methods and products
US8238515B2 (en) * 2007-08-16 2012-08-07 Caldera Pharmaceuticals, Inc. Well plate
EP2195037A2 (en) * 2007-09-10 2010-06-16 GE Healthcare UK Limited Radiofluorination methods
WO2012027555A2 (en) 2010-08-25 2012-03-01 President And Fellows Of Harvard College Glycated cd59 peptides, their preparation, and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641497A (en) * 1992-05-22 1997-06-24 Children's Hospital Of Philadelphia Gastrointestinal defensins, cDNA sequences and method for the production and use thereof
WO2001030354A1 (en) * 1999-10-26 2001-05-03 Thomas Jefferson University REGULATION OF Apob FOR DIAGNOSIS, TREATMENT AND DRUG SCREENING FOR CARDIOVASCULAR AND METABOLIC DISORDERS OR SYNDROMES

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641497A (en) * 1992-05-22 1997-06-24 Children's Hospital Of Philadelphia Gastrointestinal defensins, cDNA sequences and method for the production and use thereof
WO2001030354A1 (en) * 1999-10-26 2001-05-03 Thomas Jefferson University REGULATION OF Apob FOR DIAGNOSIS, TREATMENT AND DRUG SCREENING FOR CARDIOVASCULAR AND METABOLIC DISORDERS OR SYNDROMES

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HIGAZI ABD AL-ROOF ET AL: "Defensin stimulates the binding of lipoprotein (a) to human vascular endothelial and smooth muscle cells", BLOOD, vol. 89, no. 12, 1997, pages 4290 - 4298, XP002299296, ISSN: 0006-4971 *
TANG YI-QUAN ET AL: "Isolation, characterization, cDNA cloning, and antimicrobial properties of two distinct subfamilies of alpha-defensins from rhesus macaque leukocytes", INFECTION AND IMMUNITY, vol. 67, no. 11, November 1999 (1999-11-01), pages 6139 - 6144, XP002299297, ISSN: 0019-9567 *

Also Published As

Publication number Publication date
JP2007513063A (en) 2007-05-24
EP1634086A2 (en) 2006-03-15
WO2004106941A2 (en) 2004-12-09

Similar Documents

Publication Publication Date Title
WO2003101401A3 (en) Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
WO2004047755A3 (en) Fused bicyclic nitrogen-containing heterocycles
WO2004098377A3 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
WO2002060317A3 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
WO2002074156A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2004013180A3 (en) Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
WO2004002431A3 (en) Humanized anti-lymphotoyin beta receptor antibodies
WO2003087831A3 (en) Proteins involved in breast cancer
WO2000029574A3 (en) Inflammation-associated genes
WO2005015206A3 (en) Secreted polypeptide species associated with cardiovascular disorders
GB0124145D0 (en) Genes and proteins for prevention,prediction,prognosis and therapy of cardiovascular disease
WO2005014635A3 (en) Secreted polypeptide species reduced in cardiovascular disorders
WO2006068987A3 (en) Uses of il-23 antagonists in the treatment of diabetes mellitus
WO2004106941A3 (en) Secreted polypeptide species associated with cardiovascular disorders
WO2005058251A3 (en) Hla-dr-specific antibodies, compositions and methods
ZA200500882B (en) Polypeptides and nucleic acids encoding these and their use for the prevention, diagnosis of treatment or liver disorders and epithelial cancer
WO2005030266A3 (en) Optical imaging of colorectal cancer
WO2004090551A3 (en) Secreted polypeptide species associated with cardiovascular disorders
WO2005037236A3 (en) Novel heat shock protein 20-related polypeptides and uses therefor
WO2004083241A3 (en) Btc-interacting proteins and use thereof
WO2005003781A3 (en) Secreted polypeptide species associated with cardiovascular disorders
WO2004101615A3 (en) Secreted polypeptide species associated with cardiovascular disorders
WO2006029838A3 (en) Secreted polypeptide species involved in alzheimer’s disease
WO2004108078A3 (en) Rationally designed antibodies
WO2003087841A3 (en) An ephrin-b receptor protein involved in carcinoma

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004735211

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006529944

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2004735211

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2004735211

Country of ref document: EP